drugset / Trial / NCT02553928

Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer

NCT02553928

Phase 4 Completed 62 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluation of the safety and tolerability of a 20 mg once daily dose of memantine compared with 10 mg given twice daily in patients with dementia of Alzheimer's type and MMSE range 5-18.

Timeline

Start
2015-10
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 10 mg Oral
Subject Memantine Unknown 20 mg Oral

Indications